trial · primary record
Venetoclax
Breast Neoplasm Female
| Phase | Phase 1 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 17 |
| Primary completion | 2026-03-19 |
| Primary endpoint | Determination of the Maximum Tolerated Dose (MTD), dose-limiting toxicities (DLTs) and recommended phase 2 dose of drug combination of palbociclib, letrozole and venetoclax. |
| Registry ID | NCT03900884 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:24.372Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03900884
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Venetoclax · approval
- Venetoclax · compound